ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,431.60
      -0.04%
      US Tech 100
      19,166.40
      0.51%
      Dow Jones
      38,589.16
      -0.15%
      Brent Oil
      82.275
      0.00%
      Bitcoin
      65,988.49
      -0.03%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Gilead Sciences Inc (GILD)

      7. Gilead Sciences Inc (GILD) News

      GILD

      Gilead Sciences (GILD)

      Gilead Sciences Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:GILD
      DateTimeSourceHeadlineSymbolCompany
      6:07AMiHub NewswireFeaturedFifty 1 Labs, Inc. Announces Major Strategic Advancements and Shareholder Updates
      06/14/20243:00AMBusiness WireNew Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of TreatmentNASDAQ:GILDGilead Sciences Inc
      06/11/20247:25PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
      06/11/20247:23PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
      06/11/20247:20PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
      06/11/20247:18PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
      06/11/20247:15PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
      06/11/20247:12PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
      06/06/20244:30AMBusiness WireGilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNANASDAQ:GILDGilead Sciences Inc
      06/05/20242:00AMBusiness WireGilead’s Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary CholangitisNASDAQ:GILDGilead Sciences Inc
      06/03/202410:00AMBusiness WireKite’s Tecartus® Demonstrates Sustained Overall Survival in Adult Patients With Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaNASDAQ:GILDGilead Sciences Inc
      06/03/20249:00AMBusiness WireEncouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System LymphomaNASDAQ:GILDGilead Sciences Inc
      06/02/20248:00AMBusiness WireGilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal CancerNASDAQ:GILDGilead Sciences Inc
      06/02/20248:00AMBusiness WireGilead and Arcus Announce Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-line Metastatic Colorectal CancerNASDAQ:GILDGilead Sciences Inc
      06/01/20248:00AMBusiness WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNASDAQ:GILDGilead Sciences Inc
      06/01/20248:00AMBusiness WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNASDAQ:GILDGilead Sciences Inc
      05/31/20248:07AMBusiness WireEVOKE-01 Study Results in Metastatic NSCLC to Be Presented at an Oral Session at ASCO 2024NASDAQ:GILDGilead Sciences Inc
      05/30/20244:45PMBusiness WireGilead Provides Update on Phase 3 TROPiCS-04 StudyNASDAQ:GILDGilead Sciences Inc
      05/22/20248:30AMBusiness WireGilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024NASDAQ:GILDGilead Sciences Inc
      05/18/20248:30AMBusiness WireInvestigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary CholangitisNASDAQ:GILDGilead Sciences Inc
      05/14/202410:09AMBusiness WireKite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell TherapyNASDAQ:GILDGilead Sciences Inc
      05/09/20245:57PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
      05/09/20245:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
      05/09/20245:26PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
      05/09/20245:23PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
      05/09/20245:16PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
      05/09/20245:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
      05/09/20244:11PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:GILDGilead Sciences Inc
      05/09/20244:05PMBusiness WireKite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma ProgramNASDAQ:GILDGilead Sciences Inc
      05/09/20243:46PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:GILDGilead Sciences Inc
       Showing the most relevant articles for your search:NASDAQ:GILD